Equillium (NASDAQ:EQ) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Equillium (NASDAQ:EQ) issued its earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06, Zacks reports. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. The company had revenue of $4.39 million for the quarter.

Equillium Stock Performance

NASDAQ EQ opened at $0.41 on Friday. Equillium has a 52-week low of $0.37 and a 52-week high of $2.43. The stock has a market cap of $14.36 million, a PE ratio of -2.90 and a beta of 1.87. The firm has a 50-day moving average of $0.76 and a 200-day moving average of $0.79.

Analyst Upgrades and Downgrades

EQ has been the topic of a number of recent analyst reports. Leerink Partnrs downgraded Equillium from a “strong-buy” rating to a “hold” rating in a research report on Friday. Leerink Partners reissued a “market perform” rating and set a $1.00 target price (down from $3.00) on shares of Equillium in a report on Friday.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.